Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand

Molecular Cancer

Short Communication

Carlos O Rodriguez¹  Ralph de Vere White²  Li Xie³  Tzu-yin Lin³  Hongyong Zhang³  Sisi Wang⁴  Chong-xian Pan⁵  Bin Li⁶ 

[1] Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California-Davis, 95616, Davis, CA, USA;Department of Urology, University of California-Davis Cancer Center, 95817, Sacramento, CA, USA;Division of Hematology and oncology, Department of Internal Medicine, University of California-Davis Cancer Center, 95817, Sacramento, CA, USA;Division of Hematology and oncology, Department of Internal Medicine, University of California-Davis Cancer Center, 95817, Sacramento, CA, USA;Department of Pharmacology, Norman Bethune College of Medicine, Jilin University, Changchun, PR China;Division of Hematology and oncology, Department of Internal Medicine, University of California-Davis Cancer Center, 95817, Sacramento, CA, USA;Department of Urology, University of California-Davis Cancer Center, 95817, Sacramento, CA, USA;VA Northern California Health Care System, 10535 Hospital Way, 95655, Mather, CA, USA;Division of Hematology and oncology, Department of Internal Medicine, University of California-Davis Cancer Center, 95817, Sacramento, CA, USA;Health-coming Co. Ltd, Unit 3, No. 128 Shuang Lian Road, 314400, Haining City, Zhejiang, PR China;

关键词: Bladder Cancer;    Transitional Cell Carcinoma;    Bladder Cancer Cell;    Urothelial Cell;    Human Bladder Cancer;   

DOI  :  10.1186/1476-4598-10-9

 received in 2010-09-13, accepted in 2011-01-27,  发布年份 2011

来源: Springer

【 摘 要 】

ObjectiveTo determine if a human bladder cancer-specific peptide named PLZ4 can target canine bladder cancer cells.Experimental DesignThe binding of PLZ4 to five established canine invasive transitional cell carcinoma (TCC) cell lines and to normal canine bladder urothelial cells was determined using the whole cell binding assay and an affinitofluorescence assay. The WST-8 assay was performed to determine whether PLZ4 affected cell viability. In vivo tumor-specific homing/targeting property and biodistribution of PLZ4 was performed in a mouse xenograft model via tail vein injection and was confirmed with ex vivo imaging.ResultsPLZ4 exhibited high affinity and specific dose-dependent binding to canine bladder TCC cell lines, but not to normal canine urothelial cells. No significant changes in cell viability or proliferation were observed upon incubation with PLZ4. The in vivo and ex vivo optical imaging study showed that, when linked with the near-infrared fluorescent dye Cy5.5, PLZ4 substantially accumulated at the canine bladder cancer foci in the mouse xenograft model as compared to the control.Conclusions and Clinical RelevancePLZ4 can specifically bind to canine bladder cancer cells. This suggests that the preclinical studies of PLZ4 as a potential diagnostic and therapeutic agent can be performed in dogs with naturally occurring bladder cancer, and that PLZ4 can possibly be developed in the management of canine bladder cancer.

【 授权许可】

Unknown   
© Lin et al; licensee BioMed Central Ltd. 2011. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.